Predicting oral bioavailability (F oral ) is of importance for estimating systemic exposure of orally administered drugs. Physiologically-based pharmacokinetic (PBPK) modelling and simulation have been applied extensively in biopharmaceutics recently. The Oral Biopharmaceutical Tools (OrBiTo) project (Innovative Medicines Initiative) aims to develop and improve upon biopharmaceutical tools, including PBPK absorption models. A largescale evaluation of PBPK models may be considered the first step. Here we characterise the OrBiTo active pharmaceutical ingredient (API) database for use in a large-scale simulation study. The OrBiTo database comprised 83 APIs and 1475 study arms. The database displayed a median logP of 3.60 (2.40-4.58), human blood-to-plasma ratio of 0.62 (0.57-0.71), and fraction unbound in plasma of 0.05 (0.01-0.17). The database mainly consisted of basic compounds (48.19%) and Biopharmaceutics Classification System class II compounds (55.81%). Median human intravenous clearance was 16.9 L/h (interquartile range: 11.6-43.6 L/h; n = 23), volume of distribution was 80.8 L (54.5-239 L; n = 23). The majority of oral formulations Abbreviations: API, active pharmaceutical ingredient; AUC, area under the curve; BCS, biopharmaceutics classification system; BP, blood-to-plasma ratio; C max , maximum concentration; CL, clearance; D o , dose number according to BCS; DDI, drug-drug interaction; EFPIA, European Federation of Pharmaceutical Industries and Associations; F oral , absolute oral bioavailability; F rel , relative bioavailability; fu p , fraction unbound in plasma; IMI, Innovative Medicines Initiative; LogP, logarithm of the octanol/water partition coefficient; LogD pH , logarithm of the octanol/water partition coefficient at a given pH; M&S, modelling and simulation; MW, molecular weight; OrBiTo, Oral Biopharmaceutical Tools; P eff , effective permeability; PBPK, physiologically-based pharmacokinetic; PK, pharmacokinetics; t max , time at maximum concentration; V d , volume of distribution.
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Introduction
The oral route remains the preferred route of administration due to its ease of use and minimal invasiveness. However, an oral formulation will undergo many processes prior to entering systemic circulation, from release from formulation to dissolution of solid particles, potential precipitation, permeation, and first-pass metabolism. The prediction of absolute and relative oral bioavailability (F oral and F rel , respectively) is of great importance for anticipating the systemic exposure of orally administered formulations. For example, the ability to assess a priori when an altered state, i.e. a novel oral formulation or a change in prandial state, is likely to cause a significant change in oral drug exposure is increasingly considered of importance to successful biopharmaceutical development. F oral is governed to a large extent by the dissolution in the gastrointestinal tract, absorption, and first pass metabolism of the active pharmaceutical ingredient (API), thus schemes such as the Biopharmaceutics Classification System (BCS), which classifies a drug based on its permeability and solubility characteristics, and the Biopharmaceutics Drug Disposition Classification System (BDDCS), which classifies drugs based on its solubility and extent of metabolism (Benet et al., 2011) , have proven valuable in streamlining the experimental and/or clinical study design and ultimately providing the basis for biowaivers for freely soluble, highly permeable drugs (FDA, 2000) .
However, for more complex drugs, formulations, or drug disposition characteristics, e.g. the involvement of intestinal metabolism, active transport, or unusual dissolution behaviour, schemes such as the BCS might be considered an oversimplification, further not providing a basis for quantitative predictions. In silico physiologically-based pharmacokinetic (PBPK) modelling and simulation (M&S) have been employed for more complex biopharmaceutical problems with promising results which can be found in abundance in the literature Wu et al., 2013; Patel et al., 2014) . The application of PBPK M&S has been particularly successfully in recent years for the prediction of metabolic drug-drug interactions (DDI) and has provided the basis for waiving clinical DDI studies (Huang et al., 2013; Thondre et al., 2013) , as well as aiding in dose selection by providing drug exposure predictions for special populations such as paediatrics and organimpaired subjects (Futagami et al., 2013) . There is therefore a great incentive for an increased use of model-based methods throughout drug development.
The OrBiTo (Oral biopharmaceutics Tools) project, funded by IMI JU (Innovative Medicines Initiative Joint Undertaking), aims to develop and improve on existing tools in biopharmaceutical development. The OrBiTo project is a five year IMI consortium, bringing together nine European universities, one regulatory agency, one non-profit research organisation, four small-medium enterprises and thirteen pharmaceutical companies with the common goal of proposing innovative tools for oral biopharmaceutics. The consortium is organised in four work packages (WP): physico-chemical tools (WP-1), in vitro tools (WP-2), in vivo tools (WP-3), and in silico models (WP-4). Central to the consortium is the creation of a novel database organising physicochemical, physiological, and pharmacokinetic data for evaluation of current gaps in biopharmaceutical tools, and the improvement of these and new tools throughout the project. . A significant part of the OrBiTo initiative is the improvement of current in silico tools (Fig. 1) . A detailed review of the current state of PBPK absorption modelling can be found elsewhere (Kostewicz et al., 2013) . As a part of OrBiTo, the systematic large-scale evaluation of current PBPK absorption models is considered an essential first step in identifying where models perform, or underperform, to guide further model development. Previous large-scale efforts have been carried out to assess the predictability of PBPK models (Chang and Leblond, 1971; Parrott and Lave, 2002; Jones et al., 2006; De Buck et al., 2007; Jones et al., 2011; Poulin et al., 2011) . The OrBiTo simulation exercise intended to extend the evaluation of PBPK model performance to different software packages and absorption models, focusing on aspects relevant to oral biopharmaceutical drug development, such as a range of oral formulations, bioavailability and food effects studies, and attempting to reveal areas where in silico models and the model building process could be improved.
The OrBiTo database of APIs was intended to combine the knowledge and resources from across different EFPIA members for the purposes of enhancing drug and formulation development, specific to oral drug products and anticipation of bioavailability. It was set up in a manner where selective information could be maintained as anonymous, while providing other members of OrBiTo with useful information to further their research goals. The API datasets comprised information on the drug substances, drug moiety, formulations, and preclinical and clinical pharmacokinetic studies. Typical blinded information included the international nonproprietary and brand names of the APIs, their chemical structures and other selected compound properties, as well as the identity of the companies uploading the information. This structure allowed for companies to share information that would otherwise have been kept confidential, while still maintaining a level of anonymity. An anonymous messaging feature built into the database interface allowed for a communication link between modellers and compound owners throughout the simulation exercise for clarification of input data sources and values (Lacy-Jones et al. -Submitted) . This structure also allowed for the blinding of clinical pharmacokinetic data for the duration of the OrBiTo simulation exercise, ensuring that pure bottom-up predictions could be produced in order to analyse the predictive performance of existing in silico methods.
This manuscript summarises the current state of the OrBiTo database, and criteria for compounds to be included in the OrBiTo simulation exercise, a large scale evaluation of selected current PBPK absorption model platforms with focus on the prediction of absolute and relative oral bioavailability and oral pharmacokinetics. Details of the setup of the simulation exercise and analysis of the prediction performance of the simulations can be found in the companion manuscripts (Margolskee et al. -Part 2 -Submitted; Darwich et al. -Part 3 -Submitted).
Methods

Gap analysis & API selection criteria
The gap analysis was intended to reveal any gaps in information that may impact the results of the simulation exercise. For example, any lack of particular administered formulation types, or imbalance of relevant BCS classes. The APIs were analysed for their physicochemical properties (molecular weight, acid-base nature, logP, logD, BCS class), blood and plasma binding properties (fu p , BP), formulation characteristics, and availability and type of in vitro and preclinical clearance information. The distributions of these properties were compared with similar databases from the literature, and a subset of APIs was selected for inclusion in the OrBiTo simulation exercise, based on availability of parameter information and clinical data. Analysis in accordance to BCS classification was carried out using BCS class as reported in the OrBiTo database, the criteria for which depended upon the reporting company. If BCS class was not available in the database, then an estimated BCS classification was assigned based on fraction absorbed (f a ) estimated from scaled effective permeability (P eff ) and dose number (D o ) (see Appendix A for further details).
Comparison of the database to other sources in the literature was intended to establish the balance or reveal any imbalance of the drugs in the OrBiTo database, and to allow for prioritisation of further supplementation of the database throughout the project. Datasets used for comparison to the OrBiTo database included: The PhRMA dataset published by Poulin et al. (2011) (n = 108 compounds), the BDDCS database as published by Benet and co-workers (n = 927), Hosea et al. (2009) dataset for validation of allometric scaling of clearance (n = 50), the database of the WHO list of essential medicines as compiled by Kasim et al. (2004) (n = 123), the Pfizer compound set for testing of PBPK modelling as published by Jones et al. (2011) (n = 21) , the Johnson and Johnson dataset for testing PBPK modelling as published by De Buck et al. (2007) (n = 26), Obach et al. (2008) database of intravenous pharmacokinetic parameters (n = 670) and Bu (2006) dataset over cytochrome P450 3A4 substrates (n = 113) (Kasim et al., 2004; Bu, 2006; De Buck et al., 2007; Obach et al., 2008; Hosea et al., 2009; Benet et al., 2011; Jones et al., 2011; Poulin et al., 2011) . Potential compound overlaps between the published datasets were not considered during comparative analysis.
The minimum inclusion criteria for the simulation exercise was selected to be the availability of the following information: molecular weight, at least one logP or logD value (measured or calculated), at least one solubility point estimate or dissolution profile, measured in vitro permeability along with reference compounds necessary for scaling to P eff where applicable, any form of human in vitro clearance (e.g. in human liver microsomes, human hepatocytes, or recombinant CYP) or preclinical i.v. (allowing for allometric scaling of clearance), and human fu p .
Results
The OrBiTo database consisted of a total of 83 APIs, as submitted by EFPIA members, as of March 2014. Of these, 43 were found to satisfy the selection criteria. The 43 APIs chosen represent over 165 human studies, and over 600 human study arms. A summary of the OrBiTo database compounds and some of their physico-chemical, blood and plasma binding properties can be found in Table 1 , with check marks indicating inclusion in the simulation set. Discussion of the degree of missingness of key parameters is included in the next section. Comparison of the properties of the simulation set with the overall database, as well as with other databases from the literature, can be found in following sections. In the remaining sections, we discuss the PK study designs described in the database (species, administration routes, formulations) as well as observed in vivo characteristics (F oral , clearance (CL), and volume of distribution (V d )).
Missingness and compound selection
The degree of missingness of certain compound properties and in vitro measurements reported for the APIs in the OrBiTo database was repeatedly analysed throughout the selection process of APIs to be utilised in the simulation exercise. The main criteria restricting the inclusion of APIs in the simulation set was the availability of scalable clearance (19.3% missingness), followed by fu p measured in humans (15.7%), any solubility measurement (7.23%), and permeability with reference compounds (6.02%). A large degree of missingness was also observed relating to formulation, dissolution and solubility properties, with 22.9% of the database missing solubility vs. pH profiles, 84.3% biorelevant solubility information, 97.6% degradation rate and 56.3% particle size of solid formulations. As the simulation inclusion criteria allowed for estimation of BP human , 25.6% of the simulation set was missing this parameter. Further, certain solubility and formulation related parameters were also allowed to be missing in the simulation set, including: solubility measurements in biorelevant media (72.1% missing), particle size information (48.8%) and degradation rate (97.7%; Fig. 2 ).
The OrBiTo database contained a diverse set of clearance sources, where 28.9% of APIs were provided with clearance information from human liver microsomes, 19.3% from human hepatocytes, and 2.41% contained recombinant CYP enzyme information. A total of 60.2% of APIs came with pre-clinical data allowing for allometric scaling of clearance, of which 76.1% (48.5% of the database) included information facilitating allometric scaling using multiple pre-clinical species (Fig. 3) .
As simulation exercise inclusion criteria stipulated that any included API should include a human in vitro clearance source (such as human liver microsomes or hepatocytes) or preclinical i.v. study arms available for allometric scaling, there was a higher frequency of clearance information in the simulation set as compared to the database as a whole. In the simulation set, 39.5% of APIs had human liver microsome information, 30.2% had human hepatocyte information, and 4.65% contained recombinant CYP enzyme information (Fig. 3) . These frequencies are not mutually exclusive as 16.3% of APIs had clearance information from multiple in vitro systems.
Characterisation of the OrBiTo database compound specific properties 3.2.1. Physicochemical properties
The OrBiTo database displayed a median molecular weight (MW) of 440 g/mol (interquartile range [IQR] : 370-527.5; n = 83 APIs). The selected simulation set displayed similar molecular weights (Median: 440, IQR: 370-525; n = 43). The MW properties of the OrBiTo database were very similar to that of the PhRMA database, which displayed a median MW of 444 g/mol (range: 171-725; mean: 442.9 SD: 102, n = 108). Compared to Benet and WHO datasets both the OrBiTo and PhRMA databases displayed a higher MW (Fig. 4) (Kasim et al., 2004; Bu, 2006; Hosea et al., 2009; Benet et al., 2011; Poulin et al., 2011) .
In terms of logP, the OrBiTo database showed similar tendencies to the PhRMA database and Bu (2006) dataset, demonstrating a median logP of 3.60 (IQR: 2.40-4.58; mean: 3.57 SD: 2.13; Fig. 5 ). However, the logP of the OrBiTo database was higher than the overall average logP of 2.43 from all the datasets, suggesting the OrBiTo database consisted of slightly more lipophilic compounds compared to other databases in the literature (Kasim et al., 2004; Bu, 2006; Hosea et al., 2009; Benet et al., 2011; Poulin et al., 2011) . Dividing the OrBiTo database compounds based on acid-base nature revealed basic compounds to be the most represented group constituting 48.2% of the total database, while 16.9% of the database were acidic compounds, 22.9% ampholytes and 12.1% neutral compounds. The selected simulation set displayed a majority of basic compounds (55.8%) and a reduction in the frequency of ampholytic compounds (9.3%) compared to the overall database. The frequency distribution of acid-base nature in the database was consistent with remaining comparative datasets, where all comparators contained a majority of basic compounds ranging between 46.3 and 92.3% of the total datasets (Fig. 6 ).
Permeability, solubility and BCS classification
The OrBiTo database mostly consisted of BCS class I and II compounds, representing 18.6% and 55.8% respectively of active substances in the drug library. Although the BCS class composition of the OrBiTo database was very similar to the PhRMA dataset there was a great underrepresentation of BCS class III compounds as compared to the WHO essential drugs list (OrBiTo: 6.78% vs. WHO: 38.5%). The final selection of APIs for the simulation exercise displayed a slightly higher representation of BCS IV compounds (simulation set: 20.9% vs. database: 17.0%), whereas BCS class I and II displayed slightly lower representation in the simulation set (Fig. 7) (Kasim et al., 2004; Poulin et al., 2011) .
Preliminary estimations of D o based on the highest oral dose in the clinical data, showed a majority of OrBiTo drug substances displaying a D o ≥ 1, namely 72.9%, suggesting most compounds in the database and simulation set were solubility limited. A majority of the compounds (74.4%) displayed what could be classified as high permeability with an estimated f a ≥ 90% based on IVIVE of Caco-2 permeability information provided in the database. This is consistent with the analysis of the BCS classification, with most compounds displaying high permeability-low solubility properties (Fig. 8) .
Blood and plasma binding properties
The OrBiTo database contained a total of 108 reported blood-toplasma ratios (BP) from multiple species, of which 38.0% came from human in vitro experiments. The most commonly presented preclinical species sources of BP were rat and dog representing 25.0% and 20.4% respectively of total reported BP values. The OrBiTo database displayed a median human BP of 0.62 (IQR: 0.57-0.71), with a mean of 0.73 (SD: 0.48). On average, human BP for the OrBiTo database APIs fell below other databases from the literature, with the overall average BP of 0.86 (Fig. 9) .
The OrBiTo database contained 193 reported values of fraction unbound in plasma (fu p ) based on human and pre-clinical in vitro experiments. Human fu p was the most prevalent reported value representing 31.1% of all reported fu p 's, followed by rat and dog representing 24.4% and 19.2% respectively. Human fu p values displayed a high variability with a median fu p of 0.05 and IQR of (0.01, 0.17). A similarly wide range was seen in comparative datasets. The average fu p of the OrBiTo Fig. 5 . LogP of the OrBiTo APIs as compared to the WHO essential drugs list, PhRMA, Benet, Hosea and Bu databases (Kasim et al., 2004; Bu, 2006; Hosea et al., 2009; Benet et al., 2011; Poulin et al., 2011) . database was 0.16, which was lower as compared to comparative data sets, displaying an overall average fu p of 0.30 for all datasets (Fig. 10 ) (De Buck et al., 2007; Hosea et al., 2009; Jones et al., 2011) .
Characterisation of the OrBiTo database studies
Studies designs
At the time of the simulation exercise, the database contained 455 clinical and preclinical PK studies, consisting of a total of 1476 study arms. Of these study arms, 964 were human and represented a total of 26,469 individuals studied. The human study arms comprised close to two thirds of the total number of PK study arms, with rats and dogs representing the next most frequent species studied at 16% and 12% respectively ( Table 2) .
The number of PK study arms with orally administered drug clearly outweighed those administering intravenous (i.v.) formulations, for both human and preclinical species. While humans represented the majority of the study arms in the database (65%), only 25% of the i.v. study arms were in humans. The most frequent species in i.v. study arms was the rat at 35%, while dogs represented 23%, monkeys 10% and mice 5% (Table 2) .
Each API file in the database contained a varied number of PK study arms, ranging from 0 to 57 study arms (0 to 46 human and 0 to 35 preclinical study arms) per API (Fig. 11) . The median number of PK study arms per API was 16 (10 human, 6 preclinical), and the mean was 17.8 (11.6 human, 6.17 preclinical). 4 APIs contained no human study arms, and 26 APIs contained no preclinical study arms (3 APIs contained neither human nor preclinical study arms). Of the APIs that contained at least one preclinical PK study, the median number of preclinical study arms per API was 8 and the mean was 8.98. Fig. 11 displays the distributions of preclinical and human PK study arm counts per API.
Four different PK study types were identified in the database: i.v. vs. oral studies, ascending dose studies, formulation finding studies, and fasted vs. fed studies. i.v. vs. oral studies were defined as studies containing at least one intravenous and one oral study arm. Ascending dose studies were defined as studies containing two or more administrations of the same formulation in the same prandial state at different doses. Formulation finding studies were defined as studies containing two or more administrations of different formulations in the same prandial state. Fasted vs. fed studies were defined as studies containing at least one fasted and one fed study arm. 360 of the 455 studies fell into one or more of these categories (Table 3 ). Most of the remaining studies contained single arms with no comparison arm (77 out of the 95 unclassified study arms, or 81%). The number of APIs containing each type of study was also determined, and the results are displayed in Table 3 and Fig. 11 .
The most frequent preclinical PK study type was i.v. vs. oral (45%) followed by ascending dose (30%), formulation finding (14%) and fasted vs. fed (7.4%). In contrast, the most frequent human PK study type was ascending dose (63%) followed by formulation finding (35%) and fasted vs. fed (27%), with i.v. vs. oral studies comprising only 6%. 45 of the 83 (54%) APIs in the database contained i.v. vs. oral studies in preclinical species, whereas only 15 (18%) contained human i.v. vs. oral studies (5 additional APIs contained preclinical and 12 contained human i.v. study arms without oral study arms in the same study, thus a total of 50 APIs (60%) had preclinical and 27 APIs (32%) had human i.v. studies). The frequency of APIs containing ascending dose studies was 38.6% and 78.3% for preclinical and clinical studies, respectively. For formulation finding studies, 24.1% and 54.2%, and fasted vs. fed studies 10.8% and 51.8%. 
Formulations properties and observed bioavailability
The database contained a variety of oral formulations administered in the different studies. Immediate release made up the majority, 87.6%, of these formulations with only 7.1% prolonged release, 1.6% delayed release, and 0.5% colon targeted formulations (Fig. 12) . Of the immediate release formulations, aqueous solutions made up 30%, followed by 25% crystalline and 15% salt. The median bioavailability of immediate release formulations and immediate release solutions for APIs in the OrBiTo database is displayed in Table 4 . The bioavailability for immediate release formulations was similar in rat, dog and human (0.446, 0.456, and 0.416 respectively) compared with the PhRMA initiative (0.385, 0.497, and 0.48). However, median bioavailability in monkeys was somewhat higher in the OrBiTo database (0.629) compared with PhRMA (0.356) (Poulin et al. (2011) ).
In Vivo clearance and volume of distribution
Clearance and volumes of distribution were calculated for all i.v. study arms, in both preclinical and human subjects, following the prospective PBPK exercise and unblinding of plasma profiles. For APIs which had more than one i.v. study arm for a particular species, the geometric means of the parameters were taken. The median, 25th and 75th percentiles of the parameter values for the APIs in the database and the simulation set are displayed in Table 5 .
Human CL values for the entire database (median 16.9, 25th and 75th percentiles 11.6 and 43.6 L/h, respectively) and the simulation set (median 17.9, 25th and 75th percentiles 11.9 and 45.1 L/h) were comparable to the database of 670 compounds reported in Obach et al. (2008) , for which the median, 25th and 75th percentiles were 18, 7.65 and 45 L/h, (converted from mL/min/kg to L/h assuming 75 kg body weight). CL values were also comparable to those in Poulin et al. (2011) 699 L/h/kg for rat, dog and monkey) were also comparable to those in Poulin et al. (2011) , which reported median i.v. CL of 1.24, 0.745, 0.756 L/h/kg in rat, dog, and monkey (converted from % of liver blood flow using liver blood flows of 1.014, 18.54, and 13.08 L/h, and assuming body weights of 0.25, 10, and 4.5 kg for rat, dog and monkey).
Human V d for the entire database (median 80.8, 25th and 75th percentiles 54.5 and 239 L, respectively) and the simulation set (median 88.2, 25th and 75th percentiles 54.5 and 277 L) were slightly elevated compared to those reported in Obach et al. (2008) , for which the median, 25th and 75th percentiles were 72, 22.5 and 195 L (converted from L/kg to L assuming 75 kg body weight). However, the median V d in the OrBiTo database was less than that reported for humans in Poulin et al. (2011) (127.5 L, converted from L/kg assuming 75 kg body weight).
Discussion
The setup of OrBiTo database represents a major effort by the involved institutions to create a database of pharmaceutical compounds along with drug-and formulation-specific parameter information, clinical and preclinical data with a particular focus on oral biopharmaceutics formulations and studies. The database had several design features that allowed for recording a multitude of relevant information related to drug substances, formulations, and preclinical and clinical studies. One such example was the recording of different drug substances and formulations of the same compound, such as the possibility of different solubilities for different salt forms or different excipients used in different formulations. Experimental solubility measurements were supplemented with information on the composition of solubility media such as the specifications used for simulated fasted or fed state intestinal fluid. While experimental caco-2 measurements were accompanied by values for references compounds, users of the database should be wary that ⁎ Note that some studies fell into more than one category, and most APIs contained more than one study type, thus the sum of each column is greater than the total number of studies or APIs. i.v. = intravenous; PK = pharmacokinetic; API = active pharmaceutical ingredient.
26.3%
22.3% other in vitro assays (e.g. clearance, solubility, dissolution) did not have such information to account for inter-lab differences or allow for the establishment of in vitro in vivo correlations. The database also allowed for recording of co-administered medication and altered disease state in clinical studies, however, most of the studies recorded at the time of this gap analysis were in healthy volunteers.
The criteria for inclusion of APIs for simulation in the prospective PBPK simulation exercise were selected partly based on the minimum required parameters to run the simulation software programs, and do not represent in the least the exhaustive list of input parameters that may be necessary for accurate PBPK predictions. Considerable missingness was still apparent in the simulation set. Out of a total of 83 APIs only three initially fulfilled the minimum inclusion criteria set up independently by modellers at the University of Manchester, Sanofi and SimCYP Ltd. Relaxation of the inclusion criteria expanded the simulation set to 43 APIs by allowing estimation of BP, allowing for preclinical i.v. informed CL estimation, and allowing APIs without i.v. PK studies. Apart from these relaxed inclusion criteria, many APIs also had significant missingness in the area of biopharmaceutics related drug and formulation-specific parameters, such as solubility vs. pH profiles, biorelevant solubility measures, particle radii for solid oral formulations and more. In order to model more complex scenarios, such as dissolution, formulation effects and precipitation, it is essential to have such information.
Information related to biorelevant media, dissolution rate, particle size and participation rate is highly relevant for appropriate characterisation of oral drug absorption. The level of missingness for this information was surprising especially considering that regulatory agencies typically require information on dissolution for example as a part of bioavailability (BA) and bioequivalence (BE) studies. However, it is possible that the database contains drugs that never went through BA/BE studies for the purposes of regulatory submissions. The stage of development for the drugs included in the database is not clear, though the majority appear to be first in human, dose escalation studies. Further investigation is required to determine the reason for the missing information.
The focus of the OrBiTo project is on oral bioavailability and biopharmaceutics, thus the key interest of the simulation exercise is the predictive ability of the in silico methods to predict release, dissolution, permeation, and intestinal first-pass. In the evaluation of the predictive success of these processes, the availability of clinical i.v. data is important, as without this it is difficult to untangle these processes from systemic elimination and distribution. Only 27 of the 83 APIs in the database contained human i.v. study arms, 15 of which had i.v. and oral study arms in the same study. However, the missingness of i.v. study arms is not surprising for a dataset intended to focus on oral biopharmaceutics and formulation properties, as compounds that are ultimately intended for oral administration may never have an i.v. formulation developed. However, many pharmaceutical companies have recently made note of the importance of clearance, and have started including micro-dosing studies in their drug development plans for oral compounds (Rowland, 2012) . Despite the sparseness of APIs with i.v. data in the OrBiTo database, APIs without i.v. data had multiple oral formulations available for simulation thus allowing the testing of relative bioavailability between formulations.
While the focus of the OrBiTo project was on oral biopharmaceutics, analysis of the oral formulations in the database revealed a sparseness of nonstandard orally administered formulations (e.g. nanoparticles, microspheres, solid dispersions, and self-emulsifying delivery systems) that would have been of great relevance to the goals of the OrBiTo initiative. The large majority of oral formulations administered were immediate release (87.6%), with only 7.1% prolonged release formulations, 1.6% delayed release, and 0.5% colon targeted formulations. However, the high proportion of immediate release formulations in these numbers could be related to their overrepresentation in certain study designs, such as ascending dose studies. To provide a better context, 16.9% of the APIs in the database were administered as at least one of a prolonged, delayed, or colon target formulation, which gives a better picture of the availability of these relevant oral formulations in the database.
The comparison of the OrBiTo database to other previously published large drug datasets concluded the OrBiTo dataset to be a representative example of available drugs. Any differences may be related to the fact that the OrBiTo database reflects the research and development (R&D) portfolio, including legacy compounds and terminated projects, while, for example, the WHO list represents what is available on the market. One advantage of the OrBiTo database was its good representation of solubility-limited compounds (BCS class II), the inclusion of which has the advantage of allowing the testing of PBPK absorption models in the saturated range of solubility where one would expect more complex dissolution behaviour, and thus the possibility of poor prediction results. It also had a large representation of basic compounds, which when combined with solubility limitations have the potential to be subject to precipitation upon entering the small intestine.
Possibly one of the greatest strengths of the OrBiTo database is the multitude of APIs associated with study designs relevant to oral biopharmaceutics development such as bioavailability studies (18% of APIs), ascending dose studies (78.3%), formulation finding, (54.2%) and fasted vs. fed studies (51.8%), a focus that was not present in previous databases. Another key advantage of the database was to provide a representative sample of the R&D profile, including legacy compounds, while still enabling a completely prospective analysis of available PBPK software via the blinded nature of the database. Further details of this exercise can be found in our companion papers (Margolskee et al. 
Conclusion
The OrBiTo database provides a unique opportunity to perform a large scale evaluation of the PBPK approach to predicting oral drug bioavailability and formulation effects in human. A similar effort to test the ability of predicting biopharmaceutics has not been seen up to date. The database was found to be largely representative of previously published pharmaceutical compound datasets and reflects the API portfolio in industry R&D. Criteria for the APIs to be included in the simulation exercise were selected partly based on the parameters required for running the software programs to be tested. These criteria do not represent an exhaustive list of input parameters necessary for accurate PBPK predictions, and many APIs included in the simulation set were still suffering from significant missingness. Even in the presence of data, the quality of that information is not guaranteed. This lack of data richness Table 5 Geometric mean of clearance and volumes of distributions for preclinical i.v. studies in the database compared with the simulation set, organised by species. Values expressed as median and (25th, 75th) percentiles and n represents number of APIs. has the potential to adversely affect the interpretability of the outcome of the simulation exercise. This highlights a clear need for utilising data rich examples in a systematic test of the effects of input parameters on PBPK predictions.
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Appendix A
For grouping based on BCS class, BCS class reported in the API data file was used. If no BCS class was given then estimations of fraction absorbed (f a ) and dose number (D o ) were used to assign classification, with estimated f a ≥ 0.9 signifying highly permeable (BCS 1 & 2) and D o ≤ 1 highly soluble (BCS 1 & 3) compounds. In vitro permeability measured in Caco-2 cell monolayers was scaled to P eff using a power-model fit to lab-specific Caco-2 apparent permeability (P app ) of reference compounds and their associated P eff values measured via Loc-I-Gut (Lennernas et al., 1997) .
These calibrated P eff values were then converted to estimated f a (Eq. (2)), and grouping of APIs by f a was carried out according to the BCS f a cut-off point of 0.9 (Amidon et al., 1995; Yu and Amidon, 1999) .
Calculations of D o were based on the maximum reported dose (M o ) in the clinical data set of the corresponding API file. The solubility (C s ) was informed by the minimum reported aqueous solubility over the physiological pH range and the concomitant fluid intake (V o ) was assumed to be 250 mL (Eq. (3); Amidon et al., 1995) .
In cases where temperature of the solubility measure and melting point were given, solubility was corrected to estimated solubility at 37°C using Eq. (4), where λ is the nonideality of system, x A is the mole fraction of the solute along the saturation line (sat); h is the 
